Brief: XBiotech Achieves Milestone For Production Of Its New Potential Blockbuster Anti-Il-1⍺ Therapy
22/07/2020 18:15
July 22 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ACHIEVES MILESTONE FOR PRODUCTION OF ITS NEW
POTENTIAL
BLOCKBUSTER ANTI-IL-1⍺ THERAPY
* XBIOTECH INC - RESEARCH AND DEVELOPMENT TEAM HAS NOW
SUCCESSFULLY ENGINEERED A CELL-BASED PRODUCTION SYSTEM FOR FIRST
OF ITS NEW ANTI-IL-1⍺ ANTIBODIES
Source text for Eikon: urn:newsml:reuters.com:*:nGNX60mYVN
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke